Nasdaq
$2.71▲ 2.07%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $217.1MShares out 80.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 1d agoAfter-hours26.10.24 05:154Ownership#●●●
BridgeBio Oncology Therapeutics, Inc.
Insider Cobo Marc of BridgeBio Oncology Therapeutics, Inc. reported a change in beneficial ownership of securities as of October 21, 2026. This filing is a Form 4 statement regarding the insider's equity position.…more
$2.71+2.07%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:144Ownership
BridgeBio Oncology Therapeutics, Inc.
Insider Marc Cobo of BridgeBio Oncology Therapeutics, Inc. filed a Form 4 on October 5, 2026, reporting a change in beneficial ownership of securities effective October 1, 2026. This filing serves as the official record of the insider's equity transaction.…more
$2.71+2.07%vs prev closeView filingShare - 10.5After-hours26.10.06 05:134Ownership
BridgeBio Oncology Therapeutics, Inc.
Insider Elmelech Idan of BridgeBio Oncology Therapeutics, Inc. reported a change in beneficial ownership of securities effective October 1, 2026. This filing is a standard Form 4 disclosure regarding insider holdings.…more
$2.71+2.07%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12After-hours26.10.13 05:05#●●●
BridgeBio Oncology Therapeutics Grants Stock Options to New Employee
BridgeBio Oncology Therapeutics has granted stock options for 90,000 shares to a new employee as a material inducement for employment. This is a standard compensation procedure and does not reflect a change in the company's financial performance.…more
$2.71+2.07%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.8After-hours26.09.09 05:27
●●●●●●●● ●●●●● ●●●●●●
BridgeBio's BBO-8520 monotherapy demonstrated a 63% objective response rate in patients with 2L+ KRAS G12C non-small cell lung cancer. The company also outlined a timeline for upcoming clinical data updates for its oncology pipeline through 2027.…more
$2.71+2.07%vs prev closeShareBenzinga - 9.8After-hours26.09.09 05:05
●●●●●●●● ●●●●● ●●●●●●
BBOT reported encouraging clinical results for its KRAS G12C inhibitor BBO-8520 and announced a strategic focus on its oncology pipeline. The company maintains a strong balance sheet with sufficient cash to fund operations into 2028.…more
$2.71+2.07%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report